首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3974篇
  免费   432篇
  国内免费   6篇
耳鼻咽喉   13篇
儿科学   157篇
妇产科学   66篇
基础医学   482篇
口腔科学   55篇
临床医学   488篇
内科学   823篇
皮肤病学   214篇
神经病学   265篇
特种医学   200篇
外科学   506篇
综合类   116篇
一般理论   2篇
预防医学   442篇
眼科学   39篇
药学   388篇
中国医学   4篇
肿瘤学   152篇
  2021年   50篇
  2020年   33篇
  2019年   45篇
  2018年   52篇
  2017年   39篇
  2016年   63篇
  2015年   59篇
  2014年   80篇
  2013年   128篇
  2012年   166篇
  2011年   184篇
  2010年   119篇
  2009年   97篇
  2008年   194篇
  2007年   172篇
  2006年   185篇
  2005年   183篇
  2004年   163篇
  2003年   157篇
  2002年   134篇
  2001年   131篇
  2000年   134篇
  1999年   112篇
  1998年   60篇
  1997年   71篇
  1996年   58篇
  1995年   58篇
  1994年   49篇
  1993年   51篇
  1992年   93篇
  1991年   79篇
  1990年   87篇
  1989年   75篇
  1988年   75篇
  1987年   68篇
  1986年   78篇
  1985年   94篇
  1984年   57篇
  1983年   67篇
  1982年   36篇
  1981年   27篇
  1980年   31篇
  1979年   42篇
  1978年   41篇
  1977年   41篇
  1976年   41篇
  1975年   47篇
  1974年   49篇
  1973年   34篇
  1972年   32篇
排序方式: 共有4412条查询结果,搜索用时 28 毫秒
1.
2.
3.

Background

Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.

Objectives

The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.

Methods

Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.

Results

Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.

Conclusions

In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy.  相似文献   
4.
5.
6.
7.
8.
9.
This study aimed to assess the technical aspects of atrial septal defect (ASD) closure using the Amplatzer septal occluder (ASO) and the Gore Helex septal occluder (GHSO) for infants weighing less than 8 kg and to determine the safety, effectiveness, and near-to-intermediate-term outcome of the closure. The Mid-Atlantic Group of Interventional Cardiology Registry of percutaneous, transcatheter ASD closure procedures was reviewed for this analysis. Patients from 10 hospitals in the United States were included. The cohort for this report consisted of 68 patients weighing less than 8 kg (range, 2.3–7.8 kg; mean, 5.5 ± 1.6 kg) and ranging in age from 1 to 24 months (mean, 8.6 ± 4.7 months). The indications for ASD closure were failure to thrive, significant right heart enlargement, shunts otherwise thought to be hemodynamically significant, and poor overall clinical status. Devices were successfully implanted in 66 of the 68 infants (97.1 % procedural success rate). Five minor procedure-related complications occurred. At follow-up assessment, clinical status had improved significantly as measured by improved weight gain and decreased ventilator or oxygen dependence. All residual shunts spontaneously closed during the follow-up period. Six late deaths occurred, none of which were clearly device related. The ASO and GHSO can be safely and effectively implanted for ASD closure in infants weighing less than 8 kg. These procedures usually are successful and seldom complicated, resulting in significant clinical improvement.  相似文献   
10.
Autoimmune hemolytic anemia is a type of hemolytic anemia characterized by autoantibodies directed against red blood cells shortening their survival. When autoimmune hemolytic anemia is secondary to a paraneoplastic process, severe anemia can occur leading to significant morbidity and even mortality. Here we discuss the literature and present the case of a child with autoimmune hemolytic anemia from a paraneoplastic syndrome secondary to a renal tumor.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号